ESR1 and neoplasm: A multifactorial survival analysis of non–pCR patients who underwent neoadjuvant therapy revealed that high residual tumor Ki67 expression was a risk factor for recurrence and metastasis, whereas changes in residual tumor ER, PR, and Ki67 before and after neoadjuvant therapy were not correlated with prognosis.